Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 0.3% – Here’s What Happened

Xilio Therapeutics, Inc. (NASDAQ:XLO) shares dropped 0.3% during trading on Monday . The company traded as low as $7.60 and last traded at $7.68. Approximately 22,149 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 61,076 shares. The stock had previously closed at $7.70.

Wall Street Analyst Weigh In

XLO has been the topic of a number of analyst reports. Weiss Ratings lowered shares of Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 26th. Wall Street Zen lowered shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Xilio Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $28.00.

Xilio Therapeutics Stock Performance

The stock’s fifty day moving average price is $8.25 and its two-hundred day moving average price is $8.60.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.08. The business had revenue of $12.65 million during the quarter, compared to the consensus estimate of $8.52 million. Xilio Therapeutics had a negative net margin of 58.52% and a negative return on equity of 151.42%.

Hedge Funds Weigh In On Xilio Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bain Capital Life Sciences Investors LLC increased its position in Xilio Therapeutics by 61.4% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,372,686 shares of the company’s stock valued at $4,720,000 after acquiring an additional 2,805,869 shares during the period. Ghisallo Capital Management LLC acquired a new position in Xilio Therapeutics in the 4th quarter valued at approximately $713,000. Frazier Life Sciences Management L.P. acquired a new position in Xilio Therapeutics in the 4th quarter valued at approximately $3,787,000. Velan Capital Investment Management LP acquired a new position in Xilio Therapeutics in the 4th quarter valued at approximately $109,000. Finally, State Street Corp increased its position in Xilio Therapeutics by 13.7% in the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after acquiring an additional 22,500 shares during the period. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical?stage biotechnology company focused on the discovery and development of tumor?targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro?drug versions of potent immune?modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin?12 (IL?12) and interleukin?2 (IL?2) molecules fused to tumor?binding antibodies or peptide ligands.